{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:27:05Z","timestamp":1787596025805,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,14]]},"DOI":"10.7759\/cureus.101562","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:28:26Z","timestamp":1768447706000},"source":"Crossref","is-referenced-by-count":1,"title":["Multifocal Breast Cancer With Discordant Molecular Profiles in a Patient With NF1 and MUTYH Germline Variants: A Case Report"],"prefix":"10.7759","author":[{"given":"Lisa","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Y","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Narasimhamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0552","article-title":"The role of genetic testing in patients with breast cancer: a review","volume":"152","author":"Valencia OM","year":"2017","unstructured":"Valencia OM, Samuel SE, Viscusi RK, Riall TS, Neumayer LA, Aziz H. The role of genetic testing in patients with breast cancer: a review. JAMA Surg. 2017, 152:589-94. 10.1001\/jamasurg.2017.0552","journal-title":"JAMA Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff AC","year":"2018","unstructured":"Wolff AC, Hammond ME, Allison KH, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018, 36:2105-22. 10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"ref3","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment. breast, ovarian, pancreatic, and prostate. (2025). Accessed: 2026: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf."},{"key":"ref4","unstructured":"Invitae family history tool. (2026). Accessed. 2025: https:\/\/familyhistory.invitae.com\/pedigrees\/pedigree\/."},{"key":"ref5","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment. colorectal, endometrial, and gastric. (2025). Accessed: January 2, 2026: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_ceg.pdf."},{"key":"ref6","article-title":"Pathological characteristics of both tumors in bifocal and bicentric breast cancer","volume":"35","author":"Mosbah R","year":"2015","unstructured":"Mosbah R, Rouzier R, Guinebreti\u00e8re JM, Falcou MC, Stevens D, H\u00e9quet D. Pathological characteristics of both tumors in bifocal and bicentric breast cancer. Anticancer Res. 2015, 35:5111-6.","journal-title":"Anticancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.10.006","article-title":"Morphologic and molecular subtype status of individual tumor foci in multiple breast carcinoma. A study of 155 cases with analysis of 463 tumor foci","volume":"45","author":"Boros M","year":"2014","unstructured":"Boros M, Ilyes A, Nechifor Boila A, Moldovan C, Eniu A, Stolnicu S. Morphologic and molecular subtype status of individual tumor foci in multiple breast carcinoma. A study of 155 cases with analysis of 463 tumor foci. Hum Pathol. 2014, 45:409-16. 10.1016\/j.humpath.2013.10.006","journal-title":"Hum Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2013-0566-CP","article-title":"Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast","volume":"138","author":"Fitzgibbons PL","year":"2014","unstructured":"Fitzgibbons PL, Dillon DA, Alsabeh R, et al.. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2014, 138:595-601. 10.5858\/arpa.2013-0566-CP","journal-title":"Arch Pathol Lab Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPZSV2W1CPGRJW","article-title":"HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?","volume":"140","author":"Bethune GC","year":"2013","unstructured":"Bethune GC, Mullen JB, Chang MC. HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?. Am J Clin Pathol. 2013, 140:588-92. 10.1309\/AJCPZSV2W1CPGRJW","journal-title":"Am J Clin Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07281-2","article-title":"Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study","volume":"205","author":"Finsterbusch K","year":"2024","unstructured":"Finsterbusch K, van Diest PJ, Focke CM. Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study. Breast Cancer Res Treat. 2024, 205:413-21. 10.1007\/s10549-024-07281-2","journal-title":"Breast Cancer Res Treat"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius E","year":"2021","unstructured":"Legius E, Messiaen L, Wolkenstein P, et al.. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021, 23:1506-13. 10.1038\/s41436-021-01170-5","journal-title":"Genet Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-019-0110-z","article-title":"Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature","volume":"17","author":"Suarez-Kelly LP","year":"2019","unstructured":"Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE. Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. Hered Cancer Clin Pract. 2019, 17:12. 10.1186\/s13053-019-0110-z","journal-title":"Hered Cancer Clin Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0651-6","article-title":"Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study","volume":"22","author":"Evans DG","year":"2020","unstructured":"Evans DG, Kallionp\u00e4\u00e4 RA, Clementi M, et al.. Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genet Med. 2020, 22:398-406. 10.1038\/s41436-019-0651-6","journal-title":"Genet Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0633-8","article-title":"A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients","volume":"22","author":"LaDuca H","year":"2020","unstructured":"LaDuca H, Polley EC, Yussuf A, et al.. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020, 22:407-15. 10.1038\/s41436-019-0633-8","journal-title":"Genet Med"},{"key":"ref15","unstructured":"gnomAD Project. Variant. 17-31229258-G-A. Genome Aggregation Database (gnomAD). (2026). Accessed: 2026: https:\/\/gnomad.broadinstitute.org\/variant\/17-31229258-G-A."},{"key":"ref16","unstructured":"National Center for Biotechnology Information. ClinVar; [VCV000233450.13]. (2026). Accessed. 2026: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/233450\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/ng828","article-title":"Inherited variants of MYH associated with somatic G:C --> T:A mutations in colorectal tumors","volume":"30","author":"Al-Tassan N","year":"2002","unstructured":"Al-Tassan N, Chmiel NH, Maynard J, et al.. Inherited variants of MYH associated with somatic G:C --> T:A mutations in colorectal tumors. Nat Genet. 2002, 30:227-32. 10.1038\/ng828","journal-title":"Nat Genet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01241.x","article-title":"APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas","volume":"76","author":"Filipe B","year":"2009","unstructured":"Filipe B, Baltazar C, Albuquerque C, et al.. APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas. Clin Genet. 2009, 76:242-55. 10.1111\/j.1399-0004.2009.01241.x","journal-title":"Clin Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.12.050","article-title":"Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study","volume":"136","author":"Cleary SP","year":"2009","unstructured":"Cleary SP, Cotterchio M, Jenkins MA, et al.. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology. 2009, 136:1251-60. 10.1053\/j.gastro.2008.12.050","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.022","article-title":"Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer","volume":"146","author":"Win AK","year":"2014","unstructured":"Win AK, Dowty JG, Cleary SP, et al.. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology. 2014, 146:1208-11.e1-5. 10.1053\/j.gastro.2014.01.022","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2005.033217","article-title":"Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP)","volume":"42","author":"Nielsen M","year":"2005","unstructured":"Nielsen M, Franken PF, Reinards TH, et al.. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet. 2005, 42:e54. 10.1136\/jmg.2005.033217","journal-title":"J Med Genet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0042-1","article-title":"Mutations of the MYH gene do not substantially contribute to the risk of breast cancer","volume":"114","author":"Beiner ME","year":"2009","unstructured":"Beiner ME, Zhang WW, Zhang S, Gallinger S, Sun P, Narod SA. Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. Breast Cancer Res Treat. 2009, 114:575-8. 10.1007\/s10549-008-0042-1","journal-title":"Breast Cancer Res Treat"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-1965-0","article-title":"MUTYH gene variants and breast cancer in a Dutch case-control study","volume":"134","author":"Out AA","year":"2012","unstructured":"Out AA, Wasielewski M, Huijts PE, et al.. MUTYH gene variants and breast cancer in a Dutch case-control study. Breast Cancer Res Treat. 2012, 134:219-27. 10.1007\/s10549-012-1965-0","journal-title":"Breast Cancer Res Treat"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0024-8","article-title":"The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk","volume":"3","author":"Slavin TP","year":"2017","unstructured":"Slavin TP, Maxwell KN, Lilyquist J, et al.. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer. 2017, 3:22. 10.1038\/s41523-017-0024-8","journal-title":"NPJ Breast Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-018-00114-4","article-title":"Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort","volume":"18","author":"Fulk K","year":"2019","unstructured":"Fulk K, LaDuca H, Black MH, et al.. Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort. Fam Cancer. 2019, 18:197-201. 10.1007\/s10689-018-00114-4","journal-title":"Fam Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-021-00285-7","article-title":"Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer","volume":"21","author":"Thompson AB","year":"2022","unstructured":"Thompson AB, Sutcliffe EG, Arvai K, et al.. Monoallelic MUTYH pathogenic variants ascertained via multi-gene hereditary cancer panels are not associated with colorectal, endometrial, or breast cancer. Fam Cancer. 2022, 21:415-22. 10.1007\/s10689-021-00285-7","journal-title":"Fam Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020315","article-title":"Prevalence and distribution of MUTYH pathogenic variants, is there a relation with an increased risk of breast cancer?","volume":"16","author":"Pe\u00f1a-L\u00f3pez J","year":"2024","unstructured":"Pe\u00f1a-L\u00f3pez J, Jim\u00e9nez-Bou D, Ru\u00edz-Guti\u00e9rrez I, et al.. Prevalence and distribution of MUTYH pathogenic variants, is there a relation with an increased risk of breast cancer?. Cancers (Basel). 2024, 16:10.3390\/cancers16020315","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Dorling L","year":"2021","unstructured":"Dorling L, Carvalho S, Allen J, et al.. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021, 384:428-39. 10.1056\/NEJMoa1913948","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu C","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, et al.. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021, 384:440-51. 10.1056\/NEJMoa2005936","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00491-3","article-title":"The ten genes for breast (and ovarian) cancer susceptibility","volume":"18","author":"Foulkes WD","year":"2021","unstructured":"Foulkes WD. The ten genes for breast (and ovarian) cancer susceptibility. Nat Rev Clin Oncol. 2021, 18:259-60. 10.1038\/s41571-021-00491-3","journal-title":"Nat Rev Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-0862-x","article-title":"Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants","volume":"22","author":"Barnes DR","year":"2020","unstructured":"Barnes DR, Rookus MA, McGuffog L, et al.. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020, 22:1653-66. 10.1038\/s41436-020-0862-x","journal-title":"Genet Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw302","article-title":"Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers","volume":"109","author":"Kuchenbaecker KB","year":"2017","unstructured":"Kuchenbaecker KB, McGuffog L, Barrowdale D, et al.. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2017, 109:10.1093\/jnci\/djw302","journal-title":"J Natl Cancer Inst"},{"key":"ref33","unstructured":"National Center for Biotechnology Information. Homo sapiens neurofibromin 1 (NF1), transcript variant 3, mRNA. NCBI Nucleotide. NM_001042492.3. (2024). Accessed. January 2, 2026: https:\/\/www.ncbi.nlm.nih.gov\/nuccore\/NM_001042492.3?report=graph."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/407916-multifocal-breast-cancer-with-discordant-molecular-profiles-in-a-patient-with-nf1-and-mutyh-germline-variants-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:28:41Z","timestamp":1768447721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/407916-multifocal-breast-cancer-with-discordant-molecular-profiles-in-a-patient-with-nf1-and-mutyh-germline-variants-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.101562","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,14]]}}}